Navigation Links
Verus Pharmaceuticals Announces Promotion of Robert W. Keith to Chief Executive Officer
Date:11/12/2007

SAN DIEGO, Nov. 12 /PRNewswire/ -- Verus Pharmaceuticals, Inc., a pediatric-oriented specialty pharmaceutical company, announced today that Robert W. Keith has been promoted to President & Chief Executive Officer. Prior to the promotion, Mr. Keith served as President & Chief Operating Officer. As a result of the promotion, Cam L. Garner now will serve exclusively as Executive Chairman.

"We are excited to announce this well-deserved promotion," said Cam L. Garner. "As a co-founder of Verus, Bob has played a critical role in the development and evolution of the company from day one to the present, including our recently announced transaction with AstraZeneca."

"I am honored to take the reins from Cam at this point in time and lead the company forward as we continue to build value in our commercial franchise and accelerate our efforts on our emerging development programs," said Robert W. Keith.

The composition of the Board of Directors will not change with the promotion of Mr. Keith. In addition to Mr. Garner and Mr. Keith, the other current members include James C. Blair, Alex E. Barkas, Jean-Pierre Naegeli, Nicholas J. Simon, David F. Hale, and Erle T. Mast.

About Verus

Verus Pharmaceuticals is dedicated to improving the lives of children and those who care for them. Verus is building a portfolio of products for the unmet medical needs of children through acquisitions and alliances, with an initial focus on the treatment of asthma, allergies, and related diseases and conditions. Verus is differentiated by its pediatric orientation and its strong financial position and experienced management team, which allows the company to capitalize on an extensive network to build its product portfolio and pursue complementary transactions. The company's rigorous, disciplined approach to strategic decision-making and core competencies in development and commercialization is expected to provide significant value to its partners. More information
'/>"/>

SOURCE Verus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... The Natural Multiple Sclerosis Treatment review ... to Gary M. Levin’s cure program. , Levin ... this serious disorder. Levin says that multiple sclerosis actually ... be found in patients. , Dr. Gary M. ... years, Levin has worked with patients suffering from MS. ...
(Date:7/29/2014)... 2014 Winter is here down under, ... in Sydney’s central business district. That is, until a ... transformed the otherwise ordinary day into a celebration—a celebration ... ardent advocates of The Truth About Drugs, a drug ... . They woke up the city with a rousing ...
(Date:7/29/2014)... Daily Gossip reveals in its review that ... that will permanently eliminate all the symptoms associated to this ... will banish symptoms such as mild hearing loss, as well ... patients will be gone forever. , The method will lead ... of this program says that at the end of the ...
(Date:7/29/2014)... --,The time at which heart attack patients arrive at ... research suggests. Showing up at the emergency room ... with a 13 percent higher risk for death than ... year, more than 250,000 people suffer a ST-elevation myocardial ... which is caused by a complete blockage of blood ...
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Although the bite of ... heal well if left alone, an expert notes. ... an adverse reaction to a brown recluse spider bite, ... Poison Center, particularly since these potentially dangerous bites are ... for us to do nothing. The [bite] has classic ...
Breaking Medicine News(10 mins):Health News:Natural Multiple Sclerosis Treatment Review Reveals the Inside Story to Gary M. Levin’s Cure Program 2Health News:Sydney Business District “Rocked” by The Truth About Drugs 2Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2
... regulators told a Congressional panel today that some biological ... -- are simple enough// to produce in generic versions, ... ,Generic versions of certain biologics have been ... approval came only after manufacturers conducted rigorous human clinical ...
... of governments of Western Pacific countries in fighting tuberculosis (TB), ... control the disease. ,The region has successfully met ... of TB cases and curing at least 85 percent of ... body's TB programme. ,He was speaking at a ...
... Researchers from the decades long Framingham Heart Study, say that if ... there is a good chance// of you having lessened the risk ... continue, if your parents died young, diet and exercise may well ... published in the Archives of Internal Medicine, show that middle-aged children ...
... of industrial chemicals has suggested that we may not ... prolonged use of non-stick frying// pans and baking trays; ... penetrate into our system causing health problems, they said. ... Notification and Assessment Scheme or NICNAS said it is ...
... mattresses and TVs contain possibly hazardous chemicals called polybrominated ... National Institute of Standards and Technology and the Environmental ... ,It is not yet clear how dangerous these PBDEs ... of Europe. Their structure is strikingly similar to that ...
... soldiers who are suffering from mental illness after serving ... 18 months or longer for treatment// from the National ... figures released by British Ministry of Defence (MoD) showed ... health conditions after returning from Iraq since 2003. More ...
Cached Medicine News:Health News:Caution Urged on Biologic Drugs 2Health News:WHO Calls for Greater Efforts to Fight TB 2Health News:Take Heart If Your Parents Died at a Ripe Old Age: Framingham Heart Study 2
(Date:7/29/2014)... , July 29, 2014 New technology in ... could allow physicians to see and assess brain tissue ... according to study authors who released their findings today ... Annual Meeting in Colorado Springs, CO. ... the field of neurointervention, a specialty that facilitates stroke ...
(Date:7/29/2014)... 2014 McGraw-Hill Education Professional, a leading global ... and medical communities, has announced the launch of the ... of the world-renowned medical education platform. ... , available for download onto all iOS and Android ... gain access to valuable AccessMedicine diagnostic resources ...
(Date:7/29/2014)... CITY and TORONTO ... EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging ... the development of improved novel formulations and ... molecules announces expansion of its pharmaceutical development ... development direction includes large molecule drugs that will ...
Breaking Medicine Technology:New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4
... Seen Since Presentation at ASCO ... Alvespimycin Plus Trastuzumab Plus ... Paclitaxel Regimen, HAYWARD, Calif., Sept. ... a Phase 1 clinical,trial showing that alvespimycin, its second-generation Hsp90 inhibitor,demonstrated antitumor ...
... Sept. 7 Roche announced today that three,clinical data ... for presentation at the 2007 Breast Cancer Symposium in ... abstracts include data from the XeNA (Xeloda in NeoAdjuvant),trial, ... Herceptin in,patients with invasive breast cancer. The third presentation ...
Cached Medicine Technology:Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 2Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 3Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 4Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 5Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium 2Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium 3
Provides the security of suture and ease of automated knot tying for vascular closure of 5-8F....
... The all-new Canon CF-60DSi is an all-digital ... simple configuration, and an efficient workflow. ... mounts -- The Canon EOS-1Ds series SLR digital ... a 11.1 mega pixel resolution and the new ...
... The AIA-360 is a sophisticated Aumated Immunoassay ... This analyzer has a footprint of 16 X ... lbs. Its compact design is ideal for ... STAT testing, such as cardiac panels, as well ...
... a simple one, help physicians serve their ... the physician is provided with significantly useful ... This technical accomplishment is combined with dedicated ... The device features: High ...
Medicine Products: